Long-term outcomes after endoscopic resection of gastric adenocarcinoma of the fundic gland type and oxyntic gland adenoma: a retrospective cohort study Authors: Tomoki Yoshikawa, Masaya Iwamuro, Masahiro Nakagawa, Kazuhiro Matsueda, Sayo Kobayashi, Masao Yoshioka, Tomoki Inaba, Tatsuya Toyokawa, Tomohiro Nishina, Shouichi Tanaka, Takehiro Tanaka, Motoyuki Otsuka Published: 2026 ABSTRACT AbstractGastric adenocarcinoma of the fundic gland type (GA-FG) and oxyntic gland adenoma (OGA) are recently recognized neoplasms arising from the oxyntic mucosa; however, their long-term clinical behavior after endoscopic treatment remains poorly defined. Here, we present one of the largest multicenter cohorts with extended follow-up to clarify their long-term outcomes. We retrospectively analyzed 72 patients who underwent endoscopic resection, with a mean clinical follow-up of 68 months. No disease-specific deaths were observed during follow-up. Among 66 patients with adequate endoscopic follow-up, the mean endoscopic follow-up period was 65 months. Remarkably, no local recurrence was observed, confirming durable local control after resection. Despite this excellent prognosis, metachronous lesions developed in 3 patients (4.5%) at distinct gastric sites, all of which were successfully treated endoscopically. These findings demonstrate that GA-FG/OGA exhibit indolent behavior with outstanding long-term outcomes following endoscopic resection. However, the occurrence of metachronous tumors suggests a field cancerization-like process in the oxyntic mucosa, underscoring the need for long-term surveillance.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-58288-2.Keywords: Endoscopic resection, gastric adenocarcinoma of the fundic gland type, long-term outcomes, metachronous lesions, oxyntic gland adenomaSubject terms: Cancer, Gastroenterology, Oncology Introduction Gastric adenocarcinoma of the fundic gland type (GA-FG) and oxyntic gland adenoma (OGA) represent newly recognized neoplastic entities arising from the gastric oxyntic mucosa.1–5 According to recent clinicopathological criteria, OGA is confined to the mucosa and shows minimal or no invasion, whereas GA-FG demonstrates submucosal invasion while retaining differentiation toward fundic glandular structures.5 These lesions share overlapping histological features characterized by chief cell-predominant differentiation, but they differ in depth of invasion. However, the differences in biological behavior between OGA and GA-FG have not yet been fully elucidated. Endoscopic resection—endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR)—has become a preferred therapeutic approach for both GA-FG and OGA because they are typically detected at an early stage.6 Although short-term outcomes have been reported, data on the long-term prognosis of GA-FG/OGA after endoscopic treatment remain scarce. In particular, little is known about recurrence, metachronous lesion development, and disease-specific survival beyond five years. Clarifying these aspects is essential for establishing evidence-based surveillance strategies and counseling patients regarding their long-term risks. In this study, we evaluated the long-term clinical outcomes of patients with GA-FG/OGA who underwent endoscopic resection, focusing on recurrence patterns, metachronous lesion development, and survival over extended follow-up. Methods Study population We conducted a retrospective observational study of patients diagnosed with GA-FG/OGA who had been enrolled in our previously reported cohort.6 This original cohort comprised patients who underwent diagnostic endoscopy at Okayama University Hospital and collaborating institutions between October 2008 and February 2020. For the present investigation, 104 patients with available long-term follow-up data were initially screened (Fig. 1). The cohort analyzed in the present study partially overlaps with those included in two of our previous reports.7,8 Flowchart of patient selection. GA-FG, gastric adenocarcinoma of the fundic gland type; OGA, oxyntic gland adenoma; ESD, endoscopic submucosal dissection; EMR, endoscopic mucosal resection. To investigate outcomes after endoscopic treatment of GA-FG/OGA, we excluded 32 patients for the following reasons: three underwent primary surgical resection without prior endoscopic therapy; four had lesions that disappeared after biopsy alone and therefore did not undergo endoscopic resection; four remained untreated after diagnosis; one underwent additional surgery following ESD; and 20 had already been enrolled in another follow-up study (the RESECT-GAFG trial, an ongoing multicenter follow-up study of submucosal invasive GA-FG after endoscopic treatment). Consequently, 72 patients who had undergone endoscopic resection—either ESD or EMR—were enrolled and included in the final analysis. Surveillance endoscopy Post-resection surveillance was generally performed by periodic upper gastrointestinal endoscopy using white-light imaging. Image-enhanced endoscopy, mainly narrow band imaging or blue laser imaging, was additionally used at the discretion of the endoscopist when subtle elevated or subepithelial-like lesions were suspected. Endoscopic ultrasonography was not routinely incorporated into surveillance. Because surveillance protocols were not standardized across institutions, the influence of surveillance modality on the detection rate of metachronous lesions could not be formally evaluated. Outcomes The primary outcomes assessed were local recurrence at the resection site, development of metachronous GA-FG/OGA lesions in other parts of the stomach, overall survival, and disease-specific survival throughout the observation period. Secondary outcomes included causes of death unrelated to GA-FG/OGA. These endpoints were chosen to clarify the long-term prognosis and surveillance needs of patients treated endoscopically for GA-FG/OGA. Data collection Clinical and pathological data were retrospectively retrieved from medical records at each participating institution. Variables collected included patient demographics (age and sex), tumor location, macroscopic appearance, histological findings, depth of invasion, and treatment details. For patients presenting with multiple synchronous lesions, each lesion was counted and analyzed separately. Follow-up information, including results of surveillance endoscopy and clinical status, was obtained from scheduled visits or correspondence with referring physicians. For analyses of overall survival and disease-specific survival, the clinical follow-up duration was defined as the interval from the date of endoscopic resection (ESD or EMR) to the date of the last clinical evaluation. For analysis of endoscopic outcomes, including local recurrence at the resection site and development of metachronous GA-FG/OGA lesions in other parts of the stomach, the endoscopic follow-up duration was defined as the interval from the date of endoscopic resection to the date of the last endoscopic examination. In patients who underwent resection of two or more lesions, follow-up was calculated from the date of the first endoscopic resection. Patients who did not undergo follow-up endoscopy at least 6 months after resection were excluded from the analysis of endoscopic outcomes. Statistical analyses were performed using JMP version 19.0.4 (SAS Institute Inc., Cary, NC, USA). Continuous variables were compared using Student’s t-test or the Mann–Whitney U test, as appropriate. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate. All statistical tests were two-sided, and a p value < 0.05 was considered statistically significant. Because only three patients developed metachronous lesions, analyses of factors associated with metachronous lesion development were considered exploratory. Ethical considerations This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The protocol was reviewed and approved by the ethics committees of Okayama University Hospital (approval number 2502-035) and the institutional review boards of all other participating centers. Given the retrospective, non-interventional, and observational design of the study, the requirement for written informed consent was formally waived by each ethics committee. All investigations were performed in accordance with relevant national and institutional guidelines and regulations to ensure the protection of patient confidentiality and data integrity. Results Patient and lesion characteristics A total of 72 patients (49 men and 23 women) who underwent endoscopic resection for GA-FG/OGA were included in the analysis (Table 1). The median age at diagnosis was 67 years (range, 47–88 years). One patient initially presented with two synchronous OGA lesions and another patient presented with four GA-FG lesions; therefore, a total of 76 lesions were analyzed. Sixty-nine lesions (90.8%) were resected by ESD, and seven lesions (9.2%) were resected by EMR. Table 1Patient characteristics.CharacteristicValue (n = 72)SexMale49Female23Median age at diagnosis (years)67 (47–88)No. of initial lesions1702141Treatment of initial lesionESD69EMR7Depth of invasionT1a54T1b117T1b22Not available3Pathological outcomeEn bloc resection76Negative horizontal margin (pHM0)76Negative vertical margin (pVM0)76Lymphatic invasion negative (ly0)76Venous invasion negative (v0)76Histological R0 resection*76Mean clinical follow-up** (months)68 (0–165)OutcomeAlive69Dead from GA-FG/OGA0Dead from other causes3Mean endoscopic follow-up† (months)65 (14–165)Local recurrence0Metachronous lesions3ESD, endoscopic submucosal dissection; EMR, endoscopic mucosal resection; GA-FG, gastric adenocarcinoma of the fundic gland type; OGA, oxyntic gland adenoma.*Defined as en bloc resection with negative horizontal and vertical margins.**Defined as the interval from the date of endoscopic resection to the date of the last clinical evaluation.†Defined as the interval from the date of endoscopic resection to the date of the last endoscopic evaluation; patients without endoscopic follow-up or with follow-up of < 6 months were excluded. Patient characteristics. ESD, endoscopic submucosal dissection; EMR, endoscopic mucosal resection; GA-FG, gastric adenocarcinoma of the fundic gland type; OGA, oxyntic gland adenoma. *Defined as en bloc resection with negative horizontal and vertical margins. **Defined as the interval from the date of endoscopic resection to the date of the last clinical evaluation. †Defined as the interval from the date of endoscopic resection to the date of the last endoscopic evaluation; patients without endoscopic follow-up or with follow-up of < 6 months were excluded. The clinicopathological characteristics of the 20 patients excluded because of enrollment in the RESECT-GAFG trial are summarized in Supplementary Table S1. All lesions in the excluded cohort showed submucosal invasion, with 17 lesions (85.0%) classified as T1b1 and 3 lesions (15.0%) as T1b2; no T1a lesions were included. In contrast, the final study cohort contained a substantial proportion of T1a lesions (54 lesions, 71.1%). These differences may have contributed to enrichment of lower-risk lesions in the final study cohort. With respect to histological depth of invasion, 54 lesions (71.1%) were confined to the mucosa (T1a), corresponding to OGA; 17 lesions (22.4%) showed submucosal invasion of less than 500 μm (T1b1); and 2 lesions (2.6%) demonstrated submucosal invasion of 500 μm or greater (T1b2). In 3 lesions (3.9%), the depth of invasion could not be determined because of specimen limitations. En bloc resection was achieved in all 76 lesions (100%). Histopathological evaluation revealed negative horizontal and vertical margins and no evidence of lymphatic or venous invasion in all lesions. Accordingly, histological R0 resection was achieved in all cases. Follow-up and outcomes The mean clinical follow-up period, defined as the interval from the date of endoscopic resection to the date of the last clinical evaluation, was 68 months (range, 0–165 months; median, 66 months). Clinical follow-up information of ≥ 60 months was available for 42 patients (58.3%). At the last follow-up, 69 patients were alive, whereas 3 patients (4.2%) had died. One patient died of lung cancer 68 months after treatment for OGA, and another died of biliary cystadenocarcinoma 21 months after treatment for GA-FG. The remaining patient died 61 months after treatment for OGA; although the cause of death was unknown, no endoscopic recurrence of OGA had been observed at 21 months after treatment. Six patients who did not undergo follow-up endoscopy at least 6 months after resection were excluded from the analysis of endoscopic outcomes. In the remaining 66 patients, the mean endoscopic follow-up period for the entire cohort was 65 months (range, 14–165 months; median, 58 months). No local recurrences at the original resection sites were observed. However, three patients (4.5%) developed new metachronous GA-FG/OGA lesions in other regions of the stomach during follow-up (Fig. 2). All metachronous lesions were detected by routine surveillance endoscopy and were managed endoscopically. Representative endoscopic images of oxyntic gland adenomas (OGAs) observed in Case 2. The initial lesion found in the gastric fornix was resected by endoscopic submucosal dissection (ESD) (A). Forty-eight months after treatment, two OGAs were identified. An 8-mm OGA located on the lesser curvature of the upper gastric body was treated by ESD (B, white-light imaging; C, narrow-band imaging [NBI]). A 4-mm lesion on the anterior wall of the upper gastric body was diagnosed as OGA by biopsy; however, no residual tumor was found in the resected specimen after ESD (D, white-light imaging, arrow; E, NBI, arrow; F, after indigo carmine dye spraying, arrow). Table 2 summarizes the clinical details of the three patients who developed metachronous lesions. Case 1, a man first diagnosed with GA-FG at 68 years of age, developed a metachronous lesion 47 months after the initial treatment. ESD was performed; however, no residual lesion was identified in the resected specimen, suggesting complete removal by biopsy. Case 2, a 70-year-old woman, developed two metachronous lesions 48 months after the initial treatment. Both lesions were resected by ESD; histologically, one lesion was T1a, whereas no residual lesion was identified in the other. Case 3, a 70-year-old man, was initially diagnosed with four GA-FG lesions, all of which were resected by ESD and classified as T1b1. Subsequent metachronous lesions were detected at 11 months (one lesion, disappeared after biopsy), 14 months (three lesions: two T1a and one T1b1), and 18 months (one lesion, T1a), and all lesions were treated by ESD. Table 2Clinical details of three patients with metachronous GA-FG/OGA.Case no.Initial lesion(s)Metachronous lesion(s)SexAge*No. of lesionsTreatmentInvasion depthNo. of lesionsTime to recurrence (months)PPI/vonoprazan use at the last follow-upTreatment for metachronous lesion(s)Invasion depth1M681ESDpT1b1147YesESDNA**2F701ESDpT1a248, 48NAESDT1a, NA**3M704ESDpT1b1, pT1b1, pT1b1, pT1b1411, 14, 14, 14, 18YesESDNA**, T1a, T1a, T1b1, T1a*Age at diagnosis of the initial lesion.**Diagnosed as GA-FG/OGA on biopsy. No residual lesion was identified in the ESD specimen; therefore, the depth of invasion was undetermined, and the lesion was presumed to have been removed by biopsy.GA-FG/OGA, gastric adenocarcinoma of the fundic gland type/oxyntic gland adenoma, PPI, proton pump inhibitor; ESD, endoscopic submucosal dissection; NA, not available. Clinical details of three patients with metachronous GA-FG/OGA. *Age at diagnosis of the initial lesion. **Diagnosed as GA-FG/OGA on biopsy. No residual lesion was identified in the ESD specimen; therefore, the depth of invasion was undetermined, and the lesion was presumed to have been removed by biopsy. GA-FG/OGA, gastric adenocarcinoma of the fundic gland type/oxyntic gland adenoma, PPI, proton pump inhibitor; ESD, endoscopic submucosal dissection; NA, not available. Separate analyses according to histological subtype are summarized in Table 3. Three patients with undetermined invasion depth were excluded because histological classification as OGA or GA-FG could not be established. Patients with OGA and GA-FG showed comparable baseline characteristics, treatment modalities, and follow-up durations. No local recurrence or disease-specific death was observed in either group. Metachronous lesions developed in one patient with OGA and two patients with GA-FG; however, the difference was not statistically significant (p = 0.132). Likewise, no significant differences were observed in overall clinical outcomes between the two groups. Table 3Clinicopathological characteristics and long-term outcomes according to histological subtype (OGA vs. GA-FG).No. of patientsOGAGA-FGP value5316Sex0.760Male3612Female174Median age at diagnosis (years)68 (49–84)68 (51–88)0.395No. of lesions5419Treatment of initial lesion1.000ESD4918EMR51Mean clinical follow-up (months)70 (0–165)64 (0–134)0.530Mean endoscopic follow-up (months)67 (21–165)61 (14–125)0.476OutcomeLocal recurrence001.000Metachronous lesions120.132Disease-specific death001.000Death from other causes210.553Three lesions with undetermined depth of invasion were excluded from this analysis because histological classification as OGA or GA-FG could not be established. Data are presented as n or median (range), unless otherwise indicated.OGA, oxyntic gland adenoma; GA-FG, gastric adenocarcinoma of the fundic gland type; ESD, endoscopic submucosal dissection; EMR, endoscopic mucosal resection. Clinicopathological characteristics and long-term outcomes according to histological subtype (OGA vs. GA-FG). Three lesions with undetermined depth of invasion were excluded from this analysis because histological classification as OGA or GA-FG could not be established. Data are presented as n or median (range), unless otherwise indicated. OGA, oxyntic gland adenoma; GA-FG, gastric adenocarcinoma of the fundic gland type; ESD, endoscopic submucosal dissection; EMR, endoscopic mucosal resection. Exploratory analyses of factors potentially associated with metachronous lesion development are summarized in Table 4. Because only three patients developed metachronous lesions, multivariable analysis was not feasible. Information on proton pump inhibitor/vonoprazan use at the time of the last endoscopy during follow-up after treatment was available for 61 patients. Among the three patients with metachronous lesions, information was unavailable for one patient, whereas the remaining two patients were both receiving proton pump inhibitor/vonoprazan. Among patients without metachronous lesions, 22 were receiving proton pump inhibitor/vonoprazan and 37 were not. No significant association was observed between metachronous lesion development and PPI/vonoprazan use (p = 0.151). Likewise, no significant associations were identified for sex, age, Helicobacter pylori infection status, background gastric atrophy, or histological subtype. However, these findings should be interpreted cautiously because of the limited number of events. Table 4Exploratory analysis of factors associated with metachronous lesion development.No. of patientsMetachronous lesion (+)Metachronous lesion (−)P value363Sex1.000Male242Female121Median age at diagnosis (years)70 (68–70)68 (47–86)0.622H. pylori status1.000*Never infected022Current infection06Past infection130Undetermined25Background gastric atrophy1.000**Present126Absent133Not assessable after partial gastrectomy11PPI/vonoprazan use0.151†Yes222No037Unknown14Histological subtypeOGA (pT1a)1470.138‡GA-FG (pT1b1/pT1b2)213NA03*Never infected vs. Current/Past infection; patients with undetermined H. pylori status were excluded from this analysis. **Present vs. Absent; patients not assessable after partial gastrectomy were excluded. †Yes vs. No; patients with unknown status were excluded. ‡OGA vs. GA-FG; patients with undetermined histological subtype were excluded.OGA, oxyntic gland adenoma; GA-FG, gastric adenocarcinoma of the fundic gland type. Exploratory analysis of factors associated with metachronous lesion development. *Never infected vs. Current/Past infection; patients with undetermined H. pylori status were excluded from this analysis. **Present vs. Absent; patients not assessable after partial gastrectomy were excluded. †Yes vs. No; patients with unknown status were excluded. ‡OGA vs. GA-FG; patients with undetermined histological subtype were excluded. OGA, oxyntic gland adenoma; GA-FG, gastric adenocarcinoma of the fundic gland type. Discussion The present multicenter retrospective study evaluated the long-term clinical and endoscopic outcomes of patients with GA-FG/OGA who underwent endoscopic resection. In addition, this study represents one of the largest cohorts evaluating long-term outcomes after endoscopic resection of GA-FG/OGA. Because survival outcomes and endoscopic recurrence represent distinct aspects of prognosis, clinical follow-up and endoscopic follow-up were assessed separately in this study. The mean clinical follow-up period exceeded five years (mean, 68 months; median, 66 months), and more than half of the patients had follow-up data extending beyond 60 months. Among patients who underwent surveillance endoscopy, the mean endoscopic follow-up period was also approximately five years (mean, 65 months; median, 58 months). These extended follow-up periods provide valuable insight into the long-term natural history of GA-FG/OGA after endoscopic treatment. The principal findings of this study are twofold. First, GA-FG/OGA demonstrated an excellent long-term prognosis after endoscopic treatment. No local recurrence was observed at the resection sites, and no deaths were attributable to GA-FG/OGA during follow-up. These findings further support the concept that GA-FG/OGA generally exhibit indolent biological behavior. GA-FG and OGA are relatively recently recognized neoplastic entities arising from the oxyntic mucosa. Histologically, these lesions are characterized by differentiation toward fundic gland cells, particularly chief cells, and typically exhibit low-grade cytological atypia. Although occasional cases showing more aggressive behavior have been reported,9 oxyntic gland neoplasms are generally considered low-grade lesions with favorable outcomes. Zhang et al. performed ESD in five cases of GA-FG with submucosal invasion up to 400 μm and reported that all patients remained alive without recurrence during a median follow-up period of 16 months (range, 3–43 months).10 Similarly, He et al. treated 15 lesions (6 OGAs and 9 GA-FGs, with submucosal invasion up to 2,720 μm) using ESD and reported no recurrence during a median follow-up of 16.4 months (range, 3–47 months), with all patients surviving throughout the observation period.11 In a larger series, Hayasaka et al. reported the outcomes of ESD in 43 cases (27 OGAs and 16 GA-FGs), including one case with deep submucosal invasion.12 During a median follow-up period of 33 months (range, 9–52 months), 40 patients remained alive, while three died of causes unrelated to the disease. Although no local recurrence was observed, two patients (4.7%) developed metachronous gastric adenocarcinoma of the fundic gland type at different sites. However, these studies have been limited by relatively short follow-up periods, generally ranging from several months to less than five years. Consequently, the long-term clinical behavior of GA-FG/OGA beyond five years has remained insufficiently characterized. The present study extends these observations by demonstrating favorable outcomes over a follow-up period exceeding five years. Another notable finding of our study is the absence of local recurrence after endoscopic resection. Both ESD and EMR achieved durable local control throughout the observation period. These findings suggest that endoscopic resection is an appropriate therapeutic strategy for GA-FG/OGA when lesions are amenable to endoscopic treatment. Histological R0 resection was achieved in all lesions, which may partly explain the absence of local recurrence during long-term follow-up. Nevertheless, interpretation of these findings requires caution. Because of the exclusion criteria applied in this study, only two lesions showed submucosal invasion of ≥ 500 μm (T1b2). Therefore, the present cohort may not fully represent the clinical behavior of GA-FG with deeper submucosal invasion. The prognosis of such cases is expected to be clarified in the ongoing RESECT-GAFG trial, a multicenter study designed to investigate the long-term outcomes of patients with submucosal invasive GA-FG (T1b1 and T1b2) after endoscopic treatment, and its results will provide important complementary evidence for determining the optimal management of these tumors. Despite the excellent local control achieved by endoscopic resection, metachronous lesions were observed in three patients (4.5%) during follow-up. These lesions developed in different regions of the stomach and were detected during routine surveillance endoscopy. All metachronous tumors were successfully treated endoscopically. The occurrence of metachronous GA-FG/OGA suggests that the gastric oxyntic mucosa may harbor a tumor-prone background that predisposes patients to the development of additional lesions.13,14. Although synchronous lesions were relatively uncommon in our cohort, multifocal tumor development has been described in previous reports of GA-FG/OGA. Molecular studies have demonstrated that activation of the Wnt/β-catenin signaling pathway, most commonly through mutations in CTNNB1 or APC, plays an important role in the tumorigenesis of GA-FG.15–18 Such molecular alterations may occur independently at multiple sites in the fundic gland mucosa, resulting in the development of synchronous or metachronous tumors. These observations support the concept that GA-FG/OGA may arise within a tumor-prone field of oxyntic mucosa. GA-FG/OGA lesions are often small and may present as subtle elevated or subepithelial-like lesions, particularly in the gastric body and fundus. From a clinical perspective, the potential for multifocal tumor development therefore has important implications for surveillance strategies. Based on our findings, annual or periodic long-term endoscopic surveillance may be reasonable after endoscopic resection of GA-FG/OGA, even when durable local control has been achieved. During follow-up endoscopy, careful inspection of the entire oxyntic mucosa, particularly in the gastric body and fornix, is important for the early detection of additional lesions. White-light imaging may be complemented by image-enhanced endoscopy when small elevated, pale, or subepithelial-like lesions are suspected. Furthermore, biopsy should be considered even for subtle lesions. Information on proton pump inhibitor (PPI) or vonoprazan use during follow-up was available for most patients in this cohort. Two of the three patients who developed metachronous lesions were receiving acid-suppressive therapy at the time of the last endoscopy; however, no statistically significant association was observed between PPI/vonoprazan use and the occurrence of metachronous GA-FG/OGA. Although the biological significance of acid suppression in the development of oxyntic gland-derived neoplasms remains uncertain, long-term acid suppression has been suggested to influence the physiology and morphology of the oxyntic mucosa.19–21 Further studies with larger cohorts are therefore required to clarify whether acid-suppressive therapy contributes to the development of GA-FG/OGA. This study has several limitations. First, the retrospective design may have introduced selection bias. Second, the number of cases remained limited despite the multicenter design, reflecting the rarity of GA-FG/OGA. Third, as shown in Supplementary Table S1, patients excluded because of enrollment in the RESECT-GAFG trial exclusively had submucosal invasive lesions (GA-FG), suggesting that the present cohort may have been biased toward lower-risk disease. Fourth, molecular analyses were not systematically performed in all cases, and therefore the genetic mechanisms underlying tumor development and multiplicity could not be fully clarified. Fifth, surveillance endoscopy protocols were not standardized across participating institutions. Although surveillance generally relied on white-light imaging with additional use of image-enhanced endoscopy at the discretion of the endoscopist, variations in surveillance modality and technique may have influenced the detection of subtle lesions. Therefore, the impact of surveillance methods on the detection rate of metachronous lesions could not be formally assessed, and the true incidence of such lesions may have been underestimated. Future studies with larger cohorts and integrated molecular analyses are warranted to further clarify the biological characteristics and optimal management of these tumors. Conclusion GA-FG and OGA demonstrate excellent long-term outcomes after endoscopic resection, with no local recurrence and no disease-specific mortality observed in this cohort. These findings support endoscopic resection as an appropriate treatment strategy for these lesions. However, the occurrence of metachronous tumors indicates that careful long-term endoscopic surveillance of the remaining gastric mucosa is warranted. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations Endoscopic mucosal resection using a diathermic snare Endoscopic submucosal dissection Gastric adenocarcinoma of the fundic gland type Oxyntic gland adenoma Proton pump inhibitor Author contributions T.Y. and M.I. conceived the study and wrote the manuscript; M.N., K.M., S.K., M.Y., T.I., T. Toyokawa, T.N., and S.T. collected the data; T. Tanaka and M.O. contributed to data interpretation and critical revision of the manuscript. All authors read and approved the final manuscript. Funding No funding was received for this study. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy restrictions. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy restrictions.